San Diego – October 12, 2017 – HanAll BioPharma and Harbour BioMed signed a collaboration and license agreement to develop, manufacture and commercialize HanAll’s two novel biologics in Greater China, including Hong Kong, Macau and Taiwan. Cooley partner Kay Chandler and special counsel Rena Kaminsky advised HanAll on the transaction.
The biologics to be developed are HL161, an antibody for the treatment of autoimmune diseases, and HL036, a solution for dry eye and other inflammatory diseases.
Under the terms of the agreement, Harbour will pay HanAll up to $81 million in upfront, development, registration and milestones payments in addition to royalties on net sales. HanAll reserves the rights to develop outside of Greater China.
“We are delighted to be able to work with Harbour BioMed’s team, who have demonstrated outstanding capability in the discovery and development and commercialization of novel antibody therapeutics within the immunology field and deep expertise in China,” said Seung Kook Park, CEO of HanAll, in a news release. “This collaboration will enable us to accelerate the development and commercialization of our pipeline products in other countries too.”
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900 lawyers across 12 offices in the United States, China and Europe.